GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » Price-to-Owner-Earnings

Assembly Biosciences (FRA:V7B) Price-to-Owner-Earnings : 4.14 (As of May. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences Price-to-Owner-Earnings?

As of today (2024-05-28), Assembly Biosciences's share price is €13.65. Assembly Biosciences's Owner Earnings per Share (TTM) ended in Mar. 2024 was €3.30. It's Price-to-Owner-Earnings for today is 4.14.


The historical rank and industry rank for Assembly Biosciences's Price-to-Owner-Earnings or its related term are showing as below:

FRA:V7B' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.41   Med: 99.97   Max: 738.95
Current: 4.06

During the past 13 years, the highest Price-to-Owner-Earnings of Assembly Biosciences was 738.95. The lowest was 3.41. And the median was 99.97.


FRA:V7B's Price-to-Owner-Earnings is ranked better than
95.09% of 163 companies
in the Biotechnology industry
Industry Median: 33.11 vs FRA:V7B: 4.06

As of today (2024-05-28), Assembly Biosciences's share price is €13.65. Assembly Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-9.70. Therefore, Assembly Biosciences's PE Ratio for today is At Loss.

As of today (2024-05-28), Assembly Biosciences's share price is €13.65. Assembly Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in was €-9.70. Therefore, Assembly Biosciences's PE Ratio without NRI for today is At Loss.


Assembly Biosciences Price-to-Owner-Earnings Historical Data

The historical data trend for Assembly Biosciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Price-to-Owner-Earnings Chart

Assembly Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 4.46

Assembly Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 4.46 3.58

Competitive Comparison of Assembly Biosciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, Assembly Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Price-to-Owner-Earnings falls into.



Assembly Biosciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Assembly Biosciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=13.65/3.30
=4.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Assembly Biosciences  (FRA:V7B) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Assembly Biosciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Assembly Biosciences (FRA:V7B) Business Description

Traded in Other Exchanges
Address
331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences (FRA:V7B) Headlines

No Headlines